The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy
Cardiovascular diseases (CVDs) and metabolic disorders are major components of noncommunicable diseases, causing an enormous health and economic burden worldwide. There are common risk factors and developmental mechanisms among them, indicating the far-reaching significance in exploring the correspo...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383523000151 |
| _version_ | 1797823742436442112 |
|---|---|
| author | Yunfei Yin Mingyue Tan Lianhua Han Lei Zhang Yue Zhang Jun Zhang Wanqian Pan Jiaxiang Bai Tingbo Jiang Hongxia Li |
| author_facet | Yunfei Yin Mingyue Tan Lianhua Han Lei Zhang Yue Zhang Jun Zhang Wanqian Pan Jiaxiang Bai Tingbo Jiang Hongxia Li |
| author_sort | Yunfei Yin |
| collection | DOAJ |
| description | Cardiovascular diseases (CVDs) and metabolic disorders are major components of noncommunicable diseases, causing an enormous health and economic burden worldwide. There are common risk factors and developmental mechanisms among them, indicating the far-reaching significance in exploring the corresponding therapeutic targets. MST1/2 kinases are well-established proapoptotic effectors that also bidirectionally regulate autophagic activity. Recent studies have demonstrated that MST1/2 influence the outcome of cardiovascular and metabolic diseases by regulating immune inflammation. In addition, drug development against them is in full swing. In this review, we mainly describe the roles and mechanisms of MST1/2 in apoptosis and autophagy in cardiovascular and metabolic events as well as emphasis on the existing evidence for their involvement in immune inflammation. Moreover, we summarize the latest progress of pharmacotherapy targeting MST1/2 and propose a new mode of drug combination therapy, which may be beneficial to seek more effective strategies to prevent and treat CVDs and metabolic disorders. |
| first_indexed | 2024-03-13T10:27:29Z |
| format | Article |
| id | doaj.art-01bf1c923a8f494cb3f8fd112f6a0371 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-03-13T10:27:29Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-01bf1c923a8f494cb3f8fd112f6a03712023-05-19T04:45:26ZengElsevierActa Pharmaceutica Sinica B2211-38352023-05-0113519561975The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapyYunfei Yin0Mingyue Tan1Lianhua Han2Lei Zhang3Yue Zhang4Jun Zhang5Wanqian Pan6Jiaxiang Bai7Tingbo Jiang8Hongxia Li9Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, ChinaDepartment of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China; Department of Orthopedics, the First Affiliated Hospital of Soochow University, Suzhou 215006, China; Department of Orthopedics, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Corresponding authors.Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China; Corresponding authors.Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China; Corresponding authors.Cardiovascular diseases (CVDs) and metabolic disorders are major components of noncommunicable diseases, causing an enormous health and economic burden worldwide. There are common risk factors and developmental mechanisms among them, indicating the far-reaching significance in exploring the corresponding therapeutic targets. MST1/2 kinases are well-established proapoptotic effectors that also bidirectionally regulate autophagic activity. Recent studies have demonstrated that MST1/2 influence the outcome of cardiovascular and metabolic diseases by regulating immune inflammation. In addition, drug development against them is in full swing. In this review, we mainly describe the roles and mechanisms of MST1/2 in apoptosis and autophagy in cardiovascular and metabolic events as well as emphasis on the existing evidence for their involvement in immune inflammation. Moreover, we summarize the latest progress of pharmacotherapy targeting MST1/2 and propose a new mode of drug combination therapy, which may be beneficial to seek more effective strategies to prevent and treat CVDs and metabolic disorders.http://www.sciencedirect.com/science/article/pii/S2211383523000151MST1/2 kinasesRegulationApoptosisAutophagyImmuneCardiovascular diseases |
| spellingShingle | Yunfei Yin Mingyue Tan Lianhua Han Lei Zhang Yue Zhang Jun Zhang Wanqian Pan Jiaxiang Bai Tingbo Jiang Hongxia Li The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy Acta Pharmaceutica Sinica B MST1/2 kinases Regulation Apoptosis Autophagy Immune Cardiovascular diseases |
| title | The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy |
| title_full | The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy |
| title_fullStr | The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy |
| title_full_unstemmed | The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy |
| title_short | The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy |
| title_sort | hippo kinases mst1 2 in cardiovascular and metabolic diseases a promising therapeutic target option for pharmacotherapy |
| topic | MST1/2 kinases Regulation Apoptosis Autophagy Immune Cardiovascular diseases |
| url | http://www.sciencedirect.com/science/article/pii/S2211383523000151 |
| work_keys_str_mv | AT yunfeiyin thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT mingyuetan thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT lianhuahan thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT leizhang thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT yuezhang thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT junzhang thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT wanqianpan thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT jiaxiangbai thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT tingbojiang thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT hongxiali thehippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT yunfeiyin hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT mingyuetan hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT lianhuahan hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT leizhang hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT yuezhang hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT junzhang hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT wanqianpan hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT jiaxiangbai hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT tingbojiang hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy AT hongxiali hippokinasesmst12incardiovascularandmetabolicdiseasesapromisingtherapeutictargetoptionforpharmacotherapy |